Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products

Network of 53 Hospitals Gain Access to Masimo SET Pulse Oximeters

IRVINE, California, November 18 - Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and
Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that
Lyon, France-based Uni.H.A., one of the largest healthcare Group Purchasing
Organizations (GPO) in France, has signed a multi-year purchasing agreement
for "gold standard" Masimo SET(R) pulse oximeters. The agreement offers
preferred contract pricing to Uni.H.A.'s 53 member hospitals and provides for
more than 1,000 Masimo SET bedside pulse oximeters and 650 handheld pulse
oximeters to be purchased within four-years.

Masimo pulse oximeters feature the most advanced pulse oximetry
technology available to deliver accurate, reliable measurements and
meaningful alarms that reflect a patient's true oxygenation status. The
superior fidelity of Masimo SET pulse oximetry technology-clinically-proven
in more than 100 independent and objective studies to provide the most
trustworthy SpO2 and pulse rate measurements, even under the most difficult
clinical conditions of patient motion and low peripheral perfusion-allows
clinicians to maximize their efficiency by concentrating on caring for their
patients, rather than chasing false alarms.

In addition, the agreement provides Uni.H.A.-member hospitals with an
upgrade path to the breakthrough noninvasive blood constituent monitoring
capabilities available only as part of the Masimo Rainbow SET Pulse
CO-Oximetry technology platform. These unique noninvasive
measurements-including total hemoglobin (SpHb(TM)), oxygen content
(SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and
PVI(TM) for fluid responsiveness-can be field-installed on Masimo
Rainbow-ready devices through a simple software upgrade, allowing hospitals
to easily purchase and add them when they are ready. Masimo Rainbow SET
measurements enable earlier detection of potentially life-threatening
conditions to help increase patient safety, improve the quality of care, and
reduce the cost of care.

Jon Coleman, President of Masimo International, stated: "This agreement
with Uni.H.A. provides many of Europe's most demanding hospitals with direct
and open access to Masimo pulse oximetry and noninvasive blood constituent
monitoring solutions that facilitate faster, easier and safer health
decisions. We are happy to partner with Uni.H.A. in providing their member
hospitals with the industry-leading medical technology solutions they need to
advance patient care and outcomes."

Uni.H.A. members include 32 Hospital University Centers and 21 major
hospitals across Europe that represent 45% of French state hospital
expenditures. Today, Masimo SET pulse oximetry technology is at work in more
than 100 top-ranked hospitals throughout France, including the largest public
hospital system in Europe-Assistance Publique Hopitaux de Paris (AP-HP).

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care-helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low-Perfusion pulse
oximetry, known as Masimo SET(R), which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides
the most reliable SpO2 and pulse rate measurements even under the most
challenging clinical conditions, including patient motion and low peripheral
perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse
CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively
measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)),
carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in
addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI),
allowing early detection and treatment of potentially life-threatening
conditions. Founded in 1989, Masimo has the mission of "Improving Patient
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New
Sites and Applications." Additional information about Masimo and its products
may be found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially
and adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks related
to our assumptions regarding the repeatability of clinical results, risks
related to our assumptions that a sole-supplier agreement with Uni.H.A. will
expand European market access to Masimo SET pulse oximeters, risks related to
our belief that Masimo SET will deliver sufficient sensitivity and
specificity to deliver the most accurate and reliable measurements under all
conditions of patient motion and low peripheral perfusion, and risks related
to our assumption that this multi-year supplier agreement will serve to
broaden the use of Masimo SET pulse oximetry or will serve to provide
substantially increased revenues for the company, as well as other factors
discussed in the "Risk Factors" section of our most recent reports filed with
the Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we
do not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update, amend or
clarify these forward-looking statements or the "Risk Factors" contained in
our most recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under the
applicable securities laws.

    Media Contacts:
    Dana Banks
    Masimo Corporation
    +1-949-297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and
Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and
Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.

Media, Dana Banks of Masimo Corporation, +1-949-297-7348